Stephen X Skapek

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi request reprint PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report
    Stephen X Skapek
    Children s Medical Center and University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Pediatr Blood Cancer 60:1411-7. 2013
  2. doi request reprint Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study
    Stephen X Skapek
    Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9063, USA
    Pediatr Blood Cancer 60:1108-12. 2013
  3. pmc Temporally distinct roles for tumor suppressor pathways in cell cycle arrest and cellular senescence in Cyclin D1-driven tumor
    Hasan Zalzali
    Department of Pediatric and Adolescent Medicine, American University of Beirut, Beirut, Lebanon
    Mol Cancer 11:28. 2012

Collaborators

Detail Information

Publications3

  1. doi request reprint PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report
    Stephen X Skapek
    Children s Medical Center and University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Pediatr Blood Cancer 60:1411-7. 2013
    ..The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status...
  2. doi request reprint Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study
    Stephen X Skapek
    Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9063, USA
    Pediatr Blood Cancer 60:1108-12. 2013
    ..We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children's Oncology Group...
  3. pmc Temporally distinct roles for tumor suppressor pathways in cell cycle arrest and cellular senescence in Cyclin D1-driven tumor
    Hasan Zalzali
    Department of Pediatric and Adolescent Medicine, American University of Beirut, Beirut, Lebanon
    Mol Cancer 11:28. 2012
    ..We now attempted to define the molecular mechanisms leading to p53 activation in this model, and to identify effectors of Cyclin D1-induced senescence...